Memantine
（重定向自Akatinol）
![](/Images/godic/202412/18/Memantine_structure.svg0847.png")
![](/Images/godic/202412/18/Memantine_ball-and-stick_model0847.png")
Memantine is the first in a novel class of Alzheimer's disease medications acting on the glutamatergic system by blocking NMDA receptors. It was first synthesized by Eli Lilly and Company in 1968 as a potential agent to treat diabetes; the NMDA activity was discovered in the 1980s.